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Abstract
Endometrial cancers are mostly estrogen-dependent. FOXP1 is a P subfamily of
forkhead box (FOX), and known as an estrogen-responsive transcription factor.
The aims of this study were to examine histological location of FOXP1 in normal
and malignant endometrium, and to investigate a possible association between
FOXP1 and other factors considered to be involved in pathogenesis of endometrial
cancer. The levels of FOXP1, estrogen receptor (ER)α, and ERβ expression were
examined immunohistochemically in normal and malignant endometrium obtained
from 75 women (8 normal, 8 atypical endometrial hyperplasia, and 59 endometrial
cancers from grade 1 to 3). The effects of estrogen on ERα, FOXP1, KRAS, and
PTEN expression were analyzed in telomerase-immortalized human endometrial
stromal cells (T HESCs) by Western blotting. Western blotting was also used to
examine the effect of FOXP1 plasmid DNA or siRNA transfection on KRAS and
PTEN expression in Ishikawa cells (well differentiated endometrioid adenocarci-
noma), HEC-50B cells (poorly differentiated endometrioid adenocarcinoma), and
T HESCs, respectively. FOXP1 was expressed in normal and malignant
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endometrium, but the rate of expression was different depending upon menstrual
cycle and pathological grade of malignancy. FOXP1 expression in nucleus and
cytoplasm of grade 3 endometrioid cancers was significantly lower than that of
grade 1 and 2 ones. Estradiol increased levels of FOXP1 and KRAS expression in a
dose- and time-dependent manner in T HESCs cells, and FOXP1 transfection or
knockdown led to increase or decrease of KRAS expression but not PTEN. KRAS
expression level was significantly related to FOXP1 and ERα levels in cancer
tissues. Estradiol did not affect KRAS expression in T HESCs cells transfected
with FOXP1 siRNA. These results suggest that FOXP1 is involved in estrogen
dependent endometrial cancers through KRAS pathway.
Keywords: Medicine, Cell biology
1. Introduction
Endometrial cancer is one of the most common malignancies of female
reproductive tract and has been increasing in developed countries [1]. Endometrial
cancer is categorized into two types, Type I and Type II based on clinical features
and pathogenesis [2]. Type I endometrial cancer is estrogen-dependent and arises
in most cases before and at the time of menopause. In addition, Type I endometrial
cancer is low grade, shows good response to treatment and is the most prevalent
histological type of endometrial cancers.
With regard to pathogenesis of endometrial carcinoma, presence of abnormal
PTEN expression [3, 4, 5] and KRAS mutations [5, 6] has been proposed. PTEN
plays an important role in cell apoptosis and decreased expression of PTEN has
been shown in endometrial carcinoma [3, 4], while KRAS is an oncogene and
stimulates proliferation of endometrial cancers [5, 6]. Moreover, Li et al. reported
that epithelial cells from normal endometrium showed increased proliferation by
co-culturing with stromal cells from endometrial cancer, suggesting that the tumor
microenvironment may be involved in the pathogenesis of endometrial carcinoma
[7]. Indeed, expression of the oncogene KRAS is increased in epithelial cells
cocultured with endometrial cancer stromal cells [7]. Because estrogen synthesized
in endometrial cancer stromal cells was found to contribute to cancer cell
proliferation [8, 9], it is of importance to clarify the effects of estrogen on PTEN
and KRAS.
Recent studies have shown that the forkhead box (FOX) transcription factor family
is closely associated with hormone-dependent carcinogenesis through interaction
with the steroid receptors [10, 11, 12]. FOXP1, which belongs to the P subfamily
of FOX transcription factors, is an estrogen-responsive transcription factor [13].
Rayoo et al. found that FOXP1 expression was positively correlated with estrogen
receptor (ER) α expression in breast cancer [14] and Bates et al. found that the
pattern of expression of FOXP1 protein was similar to the pattern of expression of
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ERβ in normal breast tissue [15]. FOXP1 is widely expressed in normal human
tissues, including the uterus [16]. Immunostaining for FOXP1 has been observed in
the human endometrium, and a shift from nuclear to cytoplasmic staining was
noted between the proliferative and secretory phases of the menstrual cycle [17,
18]. The presence of nuclear FOXP1 expression was significantly linked to ERα
reactivity in normal endometrium and endometrial endometrioid adenocarcinoma
[17].
Previous studies suggested that FOXP1 behaves as an oncogene in B cell
lymphoma [19, 20] and hepatocellular carcinoma [21, 22]. Conversely, studies
suggested that FOXP1 might be a tumor suppressor gene in breast cancer [23, 24],
prostate cancer [25], and epithelial ovarian cancer [10]. Whether FOXP1 behaves
as an oncogene or a tumor suppressor gene in the pathogenesis of endometrial
conditions such as endometrial hyperplasia and endometrioid adenocarcinoma
remains unclear.
The aims of this study are 1) to determine the location and levels of FOXP1, ERα,
and ERβ expression in endometrial adenocarcinoma and endometrial hyperplasia,
and 2) to investigate a possible role of FOXP1 in pathogenesis of endometrial
cancer.
2. Materials and methods
2.1. Subjects and tissue samples
Seventy-five tissue samples were collected from patients seen at Hirosaki
University Hospital from 2009 to 2013. Thirty-five patients had grade 1
endometrioid adenocarcinoma, 13 had grade 2 endometrioid adenocarcinoma, 11
had grade 3 endometrioid adenocarcinoma, 8 had atypical endometrial hyperplasia,
and 8 had normal endometrium (5 patients were in the proliferative phase and 3
were in the secretory phase). Samples of histologically normal endometrium were
obtained from patients who underwent a hysterectomy due to a benign condition
such as uterine myoma. Endometrial phases were determined based on
hematoxylin and eosin-stained sections assessed in accordance with the
histological criteria of Noyes et al. [26]. No patients had received hormone
therapy. The histology of all of the samples was determined by 2 gynecologic
pathologists (MF and JW). This study involving the use of clinical tissue samples
was approved by the Institutional Review Board of the Hirosaki University
Graduate School of Medicine (Reference number: 2014–184). All patients were
informed of the purposes of this study and results were published on the website of
Hirosaki University Hospital. The clinical stage of endometrioid adenocarcinoma
was defined in accordance with the staging system of the International Federation
of Gynecology and Obstetrics and the grade of endometrioid adenocarcinoma was
defined in accordance with the WHO classification.
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2.2. Immunohistochemistry
All samples obtained for immunohistochemistry were fixed in formaldehyde and
embedded in paraffin. As per usual, 6-μm-thick sections were passed through
xylene and a graded ethanol series. Sections were incubated with antibodies
specific to FOXP1 (Catalog number; ab16645, Abcam, Cambridge, UK), ERα
(Catalog number; ab17087, Abcam), ERβ (Catalog number; ab288, Abcam) and
KRAS (Catalog number 60309-1-Ig, Proteintech, Chicago, IL) overnight at 4 °C
after antigen retrieval in a sodium citrate buffer. Slides were incubated with
biotinylated species-specific secondary antibodies for 20 min and then exposed to
avidin-biotinylated enzyme complex (VECTASTAIN® Elite ABC KIT, Vector
Laboratories, Burlingame, CA). Sections were treated with 0.02% diaminobenzi-
dine as a chromogen and counterstained with hematoxylin. The level of protein
expression was graded using staining scores. These scores were calculated by
multiplying the staining intensity and the stained areas within the tumors. As
shown in Fig. 1, the staining intensity in nuclei was classified as negative (score 0),
weakly positive (score 1), moderately positive (score 2), or strongly positive (score
3) [27], and the staining intensity in the cytoplasm and stroma was classified as
negative (score 0), weakly positive (score 1), or strongly positive (score 2) [17].
Stained areas were graded as follows: a score of 0 was given to a specimen with an
area of 0% staining, a score of 1 was given to a specimen with an area of ≥1% to
<25% staining, a score of 2 was given to a specimen with an area of ≥25% to
<50% staining, and a score of 3 was given to a specimen with an area of ≥50%
staining. Each slide was observed in a 0.75-mm2 field of vision using a 20 ×
objective lens. We got the staining score by multiplying staining intensity and
stained area scores together, and the sum total from 3 different sites was calculated
as the staining score. The staining score was graded in both the nuclei and the
cytoplasm of cells in glandular epithelium and stroma. The maximum score of the
nuclei staining is 27 points and that of cytoplasm of the cells and stroma is 18
points. The level of protein expression was evaluated by 2 researchers (MM and
YY) who were not given any physical and clinical information about the patient. A
staining score of 10 points or more in nuclei was defined as positive, and a staining
score of 6 points or more in cytoplasm and stroma was defined as positive.
2.3. Cell lines and cell cultures
The telomerase-immortalized human endometrial stromal cells (T HESCs) used were
from a cell line of hTERT-immortalized endometrial fibroblasts from a patient with
non-malignant myomas (CRL-4003, American Type Culture Collection, Rockville,
MD). The Ishikawa cell line established from well differentiated endometrioid
adenocarcinoma cells (JCRB1505, the Japanese Collection of Research Bioresources,
Osaka, Japan) [28] and the HEC-50B cell line derived from poorly differentiated
endometrioid adenocarcinoma (JCRB1145, the Japanese Collection of Research
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Bioresources) [29] obtained from were also used. T HESCs, Ishikawa cells, and
HEC-50B cells were cultured in RPMI 1640 medium supplemented with 10% fetal
bovine serum (FBS) at 37 °C in a water-saturated atmosphere with 5% CO2/95% air.
These 3 cell lines were verified in writing as being endometrial in origin.
2.4. Culturing in the presence of estradiol
A culturing experiment was performed in the presence of estradiol (17β-E2)
(E7785; Sigma Aldrich, St. Louis, MO). T HESCs cells and normal endometrial
stromal cells were stimulated with 2 concentrations of estradiol (100 pg/mL and
[(Fig._1)TD$FIG]
Fig. 1. Staining intensity of FOXP1, ERα and ERβ. A. Expression status of FOXP1, ERα and ERβ in
nuclei. B. Expression status of FOXP1 in cytoplasm and stroma. Evaluation of ERα and ERβ expression
was also performed by the same way as that of FOXP1 expression. Magnification of pictures of nuclei
and cytoplasm is X200 and that of stroma pictures is X400.
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10,000 pg/mL) for various periods of time (24, 48, and 72 h), and the same types of
cells were stimulated with various concentrations of estradiol (10 pg/mL, 100 pg/
mL, 1,000 pg/mL and 10,000 pg/mL) for 72 h. T HESCs were cultured for 72 h
without estradiol to serve as the control.
2.5. Transfection of FOXP1 plasmid DNA with polyethylenimine
FOXP1Human cDNA ORF Clone (vector; pCMV6-AC-GFP, Tag; C-terminal
TurbroGFP, RG216342, OriGene Technologies, Rockville, MD) was selected and
amplified, and DNA was extracted using a Hipure Plasmid Filter Maxiprep kit
(Invitrogen, Carlsbad, CA). Plasmid DNA was transfected into T HESCs, Ishikawa
cells, and HEC-50B cells with polyethylenimine (PEI). PEI and DNA were mixed
in a ratio of 3:1 and added to the cells so that the ratio of PEI to DNA would be 7.2
μg of PEI to 2.4 μg of DNA/ml. Before the mixture was added to the cells, it was
vortexed and incubated for 15 min at room temperature. Twenty-four hours after
the mixture was added, the culture medium was changed to RPMI 1640 medium
supplemented with 10% FBS. For the control group, only Tris-EDTA buffer was
mixed with PEI to dissolve DNA. The mixture was similarly added to the cells.
2.6. Assessment of green fluorescent protein expression
After incubation for 72 h, transfected cells in 10-cm dishes were evaluated for
green fluorescent protein (GFP) expression using a laser scanning confocal
microscope (BZ-X700; Keyence, Osaka, Japan), and transfection efficiency was
assessed with a digital imaging analyzer (BZ-H3C; Keyence)
2.7. Transfection of FOXP1 siRNA
FOXP1 siRNA (sc-44583, Santa Cruz Biotechnology, Santa Cruz, CA) was
transfected into T HESCs, Ishikawa cells, and HEC-50B cells according to the
manufacturer’s siRNA gene silencing protocol. In brief, 5 μl siRNA and 6 μl
siRNA Transfection Regent (sc-29528, Santa Cruz Biotechnology) were mixed and
added to the cells in siRNA Transfection Medium (sc-36868, Santa Cruz
Biotechnology), and the cells were then cultured for 6 h. RPMI 1640 medium
supplemented with 10% FBS was added and the mixture was incubated for 72 h.
Control siRNA-A (sc-36869, Santa Cruz Biotechnology) instead of FOXP1 siRNA
served as a control.
2.8. Western blot analysis
Protein samples (10 μg) were separated on a 12.5% sodium dodecyl sulfate
polyacrylamide gel and loaded and run at 30 mA for 120 min. Samples were then
blotted onto 0.45-μm nitrocellulose membranes (Catalog number 162–0114, Bio-
Rad, Hercules, CA). The membranes were incubated overnight at 4 °C with the
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following diluted antibodies: anti-KRAS (Catalog number 60309-1-Ig, Proteintech,
Chicago, IL) at 1:500, anti-PTEN (Catalog number 22034-1-AP, Proteintech) at
1:250, anti-FOXP1 (Catalog number ab16645, Abcam) at 1:500, anti-ERα (Catalog
number; ab17087, Abcam) at 1:100 and anti-β-actin (Catalog number A5441,
Sigma Aldrich) at 1:500. The membranes were then incubated with anti-mouse or
rabbit IgG HRP-linked Antibody (Catalog number 7076, Cell Signaling
Technology, Beverly, MA). Protein bands on the same membranes were visualized
using enhanced chemiluminescence (ChemiDoc XRS, Bio-Rad) according to the
manufacturer’s protocol. Band intensity was analyzed with Molecular Imager,
Image Lab Ver.3.0.1 (Bio-Rad).
2.9. Statistical analysis
All statistical analyses were performed using SPSS (version 21, SPSS Inc.,
Chicago, IL). Comparisons among the three groups were assessed using the one-
way analysis of variance (ANOVA). Statistical significance was set at P < 0.05. A
correlation between the staining scores for FOXP1, ER α, and ER β in the nuclei of
cancer cells and in the glandular epithelium was analyzed using Spearman’s
correlation coefficient. Correlations were considered significant if r > 0.4 and
p < 0.05.
3. Results
3.1. Patient characteristics
Clinical characteristics of patients are shown in Table 1. Grade 1 and grade 2
endometrioid adenocarcinoma were at a significantly earlier stage compared to
grade 3 endometrioid adenocarcinoma (P < 0.005).
3.2. FOXP1 expression
Table 2 shows an expression rate of FOXP1 in the nuclei, cytoplasm and stroma of
normal endometrium, atypical endometrial hyperplasia and endometrial adenocar-
cinoma, respectively. In the normal endometrium, the highest expression rate was
seen in the nuclei at proliferative phase (P < 0.05 vs. secretory phase). In the
endometrioid adenocarcinoma, FOXP1 was expressed in nuclei, cytoplasm and
stroma, but the expression rate in the nuclei and cytoplasm was significantly
reduced as the grade progresses (P < 0.05, respectively). FOXP1 expression in the
cytoplasm of cells was significantly greater in atypical endometrial hyperplasia
than that of endometrioid adenocarcimona at any grade (P < 0.05) (Table 2).
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3.3. Correlation between the expression rate of FOXP1 and ERα
or ERβ in nuclei
ERα and ERβ expressions in atypical endometrial hyperplasia and endometrioid
adenocarcinoma are shown in Table 3. The expression of both receptors in the
nuclei and cytoplasm differed significantly in atypical endometrial hyperplasia and
all 3 grades of endometrioid adenocarcinoma (Table 3). In particular, ERβ
expression decreased or lacked in endometrioid adenocarcinoma of any grade. The
staining scores for FOXP1 and ERα in the nuclei were significantly correlated in
atypical endometrial hyperplasia and grade 1, grade 2, and grade 3 endometrioid
adenocarcinoma (Fig. 2A, r = 0.501, p < 0.0005; r = 0.07, P < 0.01). On the other
hand, there was no significant correlation between expression of FOXP1 and ERβ
in atypical endometrial hyperplasia and grade 1 and grade 2 of endometrioid
adenocarcinoma. No significant correlation between expression of FOXP1, ERα,
or ERβ was noted in the nuclei of cells from normal endometrium (Fig. 2A and B).
3.4. The effect of sustained stimulation with estradiol on ERα,
FOXP1, KRAS, and PTEN expression
In the experiment in which T HESCs were cultured in the presence of estradiol,
levels of expression of ERα, FOXP1, and KRAS increased depending on the
concentration of estradiol and those levels also increased over time at estradiol
concentrations of 100 pg/mL and 10,000 pg/mL (Fig. 3A and B). Although
estradiol showed a slight increase in PTEN expression, the effects were not in a
dose- or time-dependent manner (Fig. 3A and B).
3.5. Transfection efficiency of FOXP1
The levels of FOXP1 transfection were evaluated by determining the level of GFP
expression. FOXP1 DNA was transfected at rates of 48% into T HESCs, 36% into
Ishikawa cells, and 36% into HEC-50B cells, respectively.
Table 1. Patient characteristics.
Clinical factor
Normal endometrium Atypical endometrial
hyperplasia (n = 8)
Endometrial adenocarcinoma
Proliferative
(n = 5)
Secretory
(n = 3)
Grade 1
(n = 35)
Grade 2
(n = 13)
Grade 3
(n = 11)
Mean age 38.4 ± 3.9 32.3 ± 1.8 47.6 ± 7.3 54.3 ± 12.2 57.8 ± 11.7 53.9 ± 10.5
FIGO Stage I/II 32 (94 %)* 10 (77 %)* 5 (45 %)
III/
IV
2 (6 %)* 3 (23 %)* 6 (55 %)
*p < 0.005 vs. grade 3 according to one-way ANOVA.
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Table 2. The location of FOXP1 positive expression.
Location Normal endometrium
p value*
Atypical endometrial hyperplasia
(n = 8) (%)
Endometrial adenocarcinoma p value*
Proliferative phase
(n = 5)(%)
Secretory phase
(n = 3)(%)
Grade 1
(n = 35)(%)
Grade 2
(n = 13)(%)
Grade 3
(n = 11)(%)
Nuclei 5 (100) 1 (33) < 0.05 5 (63) 22 (66) 7 (54) 1 (9) < 0.05
Cytoplasm 1 (20) 1 (33) 0.34 8 (100) 20 (57) 7 (54) 3 (27) < 0.05
Stroma 3 (60) 2 (67) 0.44 4 (50) 10 (29) 5 (38) 2 (18) 0.46
*One-way ANOVA.
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3.6. Effect of FOXP1 transfection on KRAS and PTEN
expression
As shown in Fig. 4, all cell lines expressed FOXP1, KRAS and PTEN at various
levels and the transfection of FOXP1 DNA increased the level of expression of
FOXP1 protein by 6 to 100 folds by densitometer measurement (Fig. 4A). FOXP1
transfection induced expression of KRAS in all cell lines. However, FOXP1
transfection suppressed the expression of PTEN protein in T HESCs, while FOXP1
transfection showed no significant changes in PTEN expression in Ishikawa and
HEC-50B cells (Fig. 4A). Meanwhile, the extra size of FOXP1 protein in Ishikawa
cells transfected with FOXP1 gene may be a protein modified by glycosylation or
phosphorylation.
The expression of FOXP1 protein decreased in all cells transfected with FOXP1
siRNA in comparison to levels in the controls (Fig. 4B). Expression of KRAS
protein decreased in all cells transfected with FOXP1 siRNA in comparison to
levels in the controls. However, levels of KRAS protein were slightly altered in T
HESCs and HEC-50B cells transfected with FOXP1 siRNA (Fig. 4B). In contrast,
the levels of expression of the PTEN protein in all cell lines transfected with
FOXP1 siRNA did not change in comparison to levels in the controls (Fig. 4B).
3.7. Positive association between the expression levels of KRAS
and FOXP1 as well as ERα in endometrioid adenocarcinoma
tissues
As a next stage, association between the expression levels of KRAS and FOXP1 as
well as ERα in endometrioid adenocarcinomas was immunohistochemically
investigated. Immunohistochemistry showed that KRAS protein was mainly
expressed in cytoplasm of cancer cell (Fig. 5). Significantly positive association
Table 3. The location of ER α and ER β positive expression.
Location Normal endometrium
(n = 8) (%)
Atypical endometrial hyperplasia
(n = 8) (%)
Endometrial adenocarcinoma p value
Grade 1
(n = 35) (%)
Grade 2
(n = 13) (%)
Grade 3
(n = 11) (%)
ER α Nuclei 8 (100) 6 (75)* 14 (40) 4 (31) 1 (9) < 0.05
Cytoplasm 8 (100) 7 (88)* 14 (40) 2 (15) 3 (27) < 0.01
Stromal 3 (38) 1 (13) 16 (46) 6 (46) 3 (27) 0.27
ER β Nuclei 3 (38) 3 (38)* 2 (6) 2 (15) 0 (0) < 0.05
Cytoplasm 7 (88) 7 (88)* 3 (9) 1 (8) 0 (0) < 0.01
Stromal 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
*p value vs. endometrial adenocarcinoma according to one-way ANOVA.
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was determined in expression levels between KRAS and FOXP1 as well as ERα in
cancer tissues (Fig. 5).
3.8. Effect of estradiol stimulation in FOXP1-knockdown cells
on KRAS expression
Finally, effect of estradiol stimulation on KRAS expression level was examined in
T HESCs transfected with FOXP1 siRNA. Estradiol did not alter the expression
level of KRAS in cells transfected with FOXP1 siRNA in a dose-dependent
manner (Fig. 6).
4. Discussion
In this study, levels of FOXP1 expression were significantly correlated with levels
of ERα expression in atypical endometrial hyperplasia and all 3 grades of
[(Fig._2)TD$FIG]
Fig. 2. The correlation between the expressions of FOXP1 and ERα or ERβ in the nuclei. A.
Correlations between FOXP1 and ERα in grade 1 and grade 2 endometrioid adenocarcinoma and
atypical endometrial hyperplasia, in grade 3 endometrioid adenocarcinoma, and in normal
endometrium. B. Correlations between FOXP1 and ERβ in grade 1 and grade 2 endometrioid
adenocarcinoma and atypical endometrial hyperplasia, and in normal endometrium.
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endometrioid adenocarcinoma. Moreover, levels of KRAS expression changed in
accordance with levels of FOXP1 expression in endometrial adenocarcinoma cells
as well as in normal stromal cells. Estradiol increased levels of FOXP1 and KRAS
expression in a time- and dose-dependent manner in T HESCs cells that abundantly
expressed ERα. These findings indicate that FOXP1 might act as an oncogene
through activation of KRAS in atypical glandular epithelium and the microenvi-
ronment around the endometrium.
A previous study has shown that loss of expression and nuclear/cytoplasmic
localization of FOXP1 expression are common events in early endometrial cancer
[17]. FOXP1 expression in the nuclei of cells decreased from 0 to 20% and FOXP1
was highly expressed in the cytoplasm of cells in early endometrial cancer [17].
The current study found that FOXP1 expression in the nuclei of cells was
significantly greater in atypical endometrial hyperplasia and in well and
moderately differentiated endometrioid adenocarcinoma than that in poorly
differentiated endometrioid adenocarcinoma. Expression of FOXP1 in the
cytoplasm was greater in atypical endometrial hyperplasia than that in all 3 grades
of endometrioid adenocarcinoma. These results suggest that a high level of FOXP1
expression may be an early event in the pathogenesis of an endometrial neoplasm.
FOXP1 expression in the nuclei of cells was significantly associated with the
expression of ERα. The association between FOXP1 expression in the nuclei of
cells and ERα expression is biologically significant since FOXP1 in the nuclei of
[(Fig._3)TD$FIG]
Fig. 3. Expression of FOXP1, ERα, KRAS and PTEN in T HESCs cells at being stimulated with
estradiol. A. Stimulation with different concentrations of estradiol. Levels of expression of ERα,
FOXP1, and KRAS increased in accordance with the concentrations of estradiol. B. Stimulation with an
estradiol concentration of 100 pg/mL and 10,000 pg/mL for different periods of time. Levels of
expression of ERα, FOXP1, and KRAS increased over time. Full, unmodified images of this figure are
available as Supplementary Material.
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cells may act as a coregulator of ERα [17] or FOXP1 may be a downstream target
of ERα. In the current study, expression levels of ERα in T HESCs cells
transfected with FOXP1 DNA or siRNA did not altered (data not shown). On the
other hand, cytoplasmic expression of FOXP1 was significantly associated with
HIF-1α overexpression and also linked with deep myometrial invasion and with
[(Fig._4)TD$FIG]
Fig. 4. Altered expression of KRAS in cells transfected with FOXP1 DNA or siRNA. A. Up-regulation
of KRAS protein in FOXP1-transfected T HESCs, Ishikawa cells and HEC-50B cells. B. Down-
regulation of KRAS protein in siRNA FOXP1-transfected T HESCs, Ishikawa cells and HEC-50B cells.
Full, unmodified images of this figure are available as Supplementary Material.
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poor differentiation in endometrial cancer [17]. Thus, further research is warranted
to confirm the exact role of cytoplasmic expression of FOXP1.
Sustained estrogen stimulation of endometrium is considered to be a risk factor of
developing type I endometrial cancer [7, 8, 30]. There is sufficient evidence that
unopposed estrogen therapy to postmenopausal women with intact uterus
significantly increased the risk of endometrial cancer [31]. In general, it is thought
that endometrial cancer develops from atypical endometrial hyperplasia, a
precursor lesion of endometrial cancer [32]. Genetic abnormalities or mutations
such as p53 mutations, KRAS mutations, phosphatidylinositol 3-kinase (PI3 K)
mutations, abnormal PTEN expression, and accumulation of β catenin are known
to be involved in malignant transformation of normal endometrium [33, 34]. In
[(Fig._5)TD$FIG]
Fig. 5. Relationship in expression levels between KRAS and FOXP1 as well as ERα in endometrioid
adenocarcinoma tissues. Note that KRAS protein was mainly expressed in cytoplasm of cancer cell.
Magnification of pictures is X200.
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addition, various abnormalities at the chromosomal level, such as microsatellite
instability and chromosomal instability i.e. genomic instability, are known to be
present during oncogenesis. These conditions are noted in the early stages of
atypical endometrial hyperplasia. In this study, we focused on estrogen-dependent
KRAS signaling, since it has been shown that mutant KRAS constantly
phosphorylates proteins downstream and activates a signaling cascade [35].
Activation of KRAS induces cell proliferation and growth and inhibits apoptosis
[36]. Abnormal activation of the Ras pathway occurs in about 40% of endometrial
cancers [37]. KRAS mutations are reported to induce the development of estrogen-
dependent tumors [35]. The present study showed that estrogen stimulated KRAS
expression and that FOXP1 transfection induced KRAS expression in a dose- and
time-dependent manner in in vitro culture system using T HESCs, Ishikawa and
HEC-50B cell lines, suggesting that an oncogenic action of estrogen on
endometrium is mediated through FOXP1 activation. A high dose of estradiol in
FOXP1 induction assay was adopted in this study because 10 to 10,000 pg/ml
concentrations of estradiol were used to explore the ability of estradiol to control
cAMP and cGMP production by human granulosa cells in culture [38]. Meanwhile,
KRAS expression is affected by epidermal growth factor receptor (EGFR) signal
transduction. Recent report showed that silencing of FOXP1 inhibits EGFR-
dependent tumor growth and, conversely, de-repression of FOXP1 increases
tumorigenicity [39], indicating genomic interaction between FOXP1 and KRAS.
However, PTEN also plays a key role in the development of type I endometrial
cancer [32]. PTEN has a variety of cancer-inhibiting capabilities, e.g. it arrests the
cell cycle, it induces apoptosis, it increases the stability of P53, and it enhances
transcriptional activation by p53 [40]. A dysfunction in PTEN leads to the
development and progression of cancer, and a somatic mutation in PTEN is noted
in 83% of type I endometrial cancers [41]. Although PTEN was induced by
estrogen administration and FOXP1 transfection reduced PTEN expression in T
[(Fig._6)TD$FIG]
Fig. 6. Effect of estradiol stimulation in FOXP1-knockdown cells on KRAS expression. T HESCs cells
transfected with FOXP1 siRNA were stimulated with various concentrations of estradiol for 72 h.
Estradiol stimulation did not affect KRAS expression in FOXP1 knockdown T HESCs cells. Full,
unmodified images of this figure are available as Supplementary Material.
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HESCs cells, no such effects were observed in Ishikawa or HEC-50B, suggesting
FOXP1 is unlikely involved in the dysfunction in PTEN. Li et al. reported that
stromal cells of endometrial carcinoma promoted proliferation of epithelial cells
through the HGF/c-Met/Akt signaling pathway [7]. PTEN belongs to Akt signaling
pathway [42]. Tumor microenvioronment participates in the endometrial carcino-
ma pathogenesis [7]. Since T HESCs cells are derived from a normal stromal cell,
the discrepant result in this study might be led by biological characterization of the
cells between stromal and cancerous tissues. Thus, other factors are involved in
inducing abnormalities in PTEN, and these factors need to be studied further.
Neoplastic changes in the endometrium begin with hyperplasia of the endometri-
um, and they lead to atypical endometrial hyperplasia, and then they progress to the
accumulation of abnormalities in various genes such as KRAS and PTEN.
Estrogen stimulation is known to be one of putative factors that are responsible for
mutations in KRAS. However, the current findings suggest that FOXP1 activates
the KRAS pathway, thus playing a role in the pathogenesis of endometrial cancer.
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